<DOC>
	<DOC>NCT02015871</DOC>
	<brief_summary>This trial is an open-label, multi-centre, single arm extension for the 000006 trial in Chinese patients with prostate cancer. Eligible patients will receive monthly (28-day intervals) maintenance doses of 80 mg (20 mg/mL) degarelix administered by subcutaneous (s.c.) injection for a period of 2 years from first visit in this extension trial. Patients, who received goserelin treatment in the main trial, will get a degarelix starting dose (240 mg; 40 mg/mL) at the first visit and continue on degarelix treatment. The purpose of this 2-year extension trial is to collect long-term safety and tolerability data for the one-month dosing regimen.</brief_summary>
	<brief_title>An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has given written informed consent before any trialrelated activity is performed. A trialrelated activity is defined as any procedure that would not have been performed during the normal management of the patient Has completed the 000006 trial Has been withdrawn/discontinued from the 000006 trial.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>